Pharma

Your Article Summary

See Latest Articles

European Commission Approval of New Indication for Roche's Pegasys (peginterferon alfa-2a) Offers Hepatitis C Patients a Second Chance for a Cure
Corporate News Releases - The Healthcare Sales & Marketing Network, 12/05/08

Roche announced that the European Commission has approved Pegasys (peginterferon alfa-2a (0 KD)) plus Copegus (ribavirin) for the retreatment of hepatitis C patients who were not successfully treated with an initial course of interferon alpha (pegylated or non-pegylated), either alone or in combination with ribavirin.

Today in Drug/Product Approvals...keeping you current

Receive free subspecialty "5-minute updates" via email

Abbott Seeks FDA Approval of New Dosage Strengths of SIMCOR
Abbott, 12/11/09

Recombinant Human Erythropoietin, Epogin Injection Application for Approval of Additional Indication of Chemotherapy-Induced Anemia
Chugai Pharmaceutical Co., 12/08/09

Synthon announces European approvals for Raloxifene
Synthon, 12/08/09

 See all of Drug/Product Approvals